Share on LinkedInShare on LinkedIn

ARTICLE · 04 NOVEMBER 2024

FDA Issues Final Guidance On DCTs And Decentralized Elements

Decentralized clinical trials (DCTs) have the potential to increase access to more representative patient populations and improve the efficiency of clinical trials.

United StatesFood, Drugs, Healthcare, Life Sciences

Improving the strength and generalizability of evidence from decentralized clinical trials

Decentralized clinical trials (DCTs) have the potential to increase access to more representative patient populations and improve the efficiency of clinical trials. Towards this end, in September, the Food and Drug Administration issued a final guidance, "Conducting Clinical Trials With Decentralized Elements," providing recommendations for sponsors, investigators, and other interested parties regarding the implementation of decentralized elements in DCTs.

This final guidance fulfills section 3606(a)(2) of the Consolidated Appropriations Act, 2023, directing FDA "to issue a final guidance that includes recommendations to clarify and advance the use of DCTs to support the development of drugs and devices."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from